Tiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks Research

Tiziana Life Sciences (NASDAQ:TLSA) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other brokerages have also recently commented on TLSA. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings lowered shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tiziana Life Sciences currently has a consensus rating of “Reduce”.

Tiziana Life Sciences Trading Down 10.5%

NASDAQ TLSA opened at $1.11 on Tuesday. The stock has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $1.36. Tiziana Life Sciences has a 12 month low of $1.04 and a 12 month high of $2.60.

Tiziana Life Sciences (NASDAQ:TLSA) last released its earnings results on Friday, May 1st. The company reported ($0.28) earnings per share for the quarter. As a group, equities analysts predict that Tiziana Life Sciences will post -0.16 earnings per share for the current year.

Hedge Funds Weigh In On Tiziana Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the 4th quarter worth approximately $30,000. Cubist Systematic Strategies LLC bought a new position in Tiziana Life Sciences in the first quarter valued at approximately $25,000. Jane Street Group LLC boosted its holdings in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after buying an additional 151,858 shares during the period. Marshall Wace LLP acquired a new position in shares of Tiziana Life Sciences in the second quarter valued at approximately $39,000. Finally, Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences during the third quarter worth $520,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.